Biotherapies occupy an increasingly important role in the arsenal of systemic treatment of moderate to severe psoriasis. The most used molecules in practice are anti-TNF alpha and interleukin inhibitors. International recommendations were established by European and English experts specifying the place of these treatments in the therapeutic strategy of the psoriasis.